BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31575382)

  • 1. Pathway Mutations in Breast Cancer Using Whole-Exome Sequencing.
    Chang YS; Chang CM; Lin CY; Chao DS; Huang HY; Chang JG
    Oncol Res; 2020 Mar; 28(2):107-116. PubMed ID: 31575382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study.
    Olivier M; Bouaoun L; Villar S; Robitaille A; Cahais V; Heguy A; Byrnes G; Le Calvez-Kelm F; Torres-Mejía G; Alvarado-Cabrero I; Imani-Razavi FS; Inés Sánchez G; Jaramillo R; Porras C; Rodriguez AC; Garmendia ML; Soto JL; Romieu I; Porter P; Guenthoer J; Rinaldi S;
    PLoS One; 2019; 14(1):e0210372. PubMed ID: 30653559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole exome sequencing of rare aggressive breast cancer histologies.
    Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
    Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
    Callens C; Driouch K; Boulai A; Tariq Z; Comte A; Berger F; Belin L; Bièche I; Servois V; Legoix P; Bernard V; Baulande S; Chemlali W; Bidard FC; Fourchotte V; Salomon AV; Brain E; Lidereau R; Bachelot T; Saghatchian M; Campone M; Giacchetti S; Zafrani BS; Cottu P
    Genome Med; 2021 Mar; 13(1):44. PubMed ID: 33722295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
    Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
    Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-exome sequencing of Finnish hereditary breast cancer families.
    Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.
    Fang Y; Ma X; Zeng J; Jin Y; Hu Y; Wang J; Liu R; Cao C
    Cell Physiol Biochem; 2018; 50(1):169-178. PubMed ID: 30278442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted gene next-generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer.
    Yao J; Chen Q; Zhu JQ; Cai RG
    J Gene Med; 2022 Jun; 24(6):e3420. PubMed ID: 35470535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing in familial breast cancer patients from Lebanon.
    Jalkh N; Chouery E; Haidar Z; Khater C; Atallah D; Ali H; Marafie MJ; Al-Mulla MR; Al-Mulla F; Megarbane A
    BMC Med Genomics; 2017 Feb; 10(1):8. PubMed ID: 28202063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
    Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
    Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
    BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Panel Testing in Hereditary Breast Cancer.
    Rostami P; Zendehdel K; Shirkoohi R; Ebrahimi E; Ataei M; Imanian H; Najmabadi H; Akbari MR; Sanati MH
    Arch Iran Med; 2020 Mar; 23(3):155-162. PubMed ID: 32126783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study.
    Shah OS; Soran A; Sahin M; Knapick BA; Ugras S; Celik E; Lucas PC; Lee AV
    Clin Breast Cancer; 2021 Jun; 21(3):210-217. PubMed ID: 33191115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.
    Cornen S; Guille A; Adélaïde J; Addou-Klouche L; Finetti P; Saade MR; Manai M; Carbuccia N; Bekhouche I; Letessier A; Raynaud S; Charafe-Jauffret E; Jacquemier J; Spicuglia S; de The H; Viens P; Bertucci F; Birnbaum D; Chaffanet M
    PLoS One; 2014; 9(1):e81843. PubMed ID: 24416132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.